GW Pharmaceuticals PLC- ADR
GW Pharmaceuticals will release its Q4/2015 earnings tomorrow, December 7 after market close. The company was originally supposed to release earnings for the quarter on December 3, but announced on November 30 they would delay the report to include new data from drug Epidiolex (R), an investigational drug for childhood-onset epilepsy. Analyst estimate revenues of $15.02 million and a loss per share of ($1.05), compared to last quarter’s revenue of $13.55 million and losses of ($1.58) per share.
In this quarter, the company posted positive results from a study on the combination of cannabinoids and schizophrenia. Specifically, the study indicated that 88% of patients who combined antiphyschoitc drugs and GWPH’s cannabinoid drug reported an improvement in symptoms, compared to those taking the placebo. In October, the company released data from its cannabinoid drug Sativex intended to treat cancer pain. Marie Fallon, principle investigator of the drug’s Phase 3 program, stated, “While the results overall have been disappointing, and not necessarily wholly consistent with clinical experience, nonetheless they suggest that Sativex may have a useful role in the treatment of certain subgroups of patients with advanced cancer pain who have exhausted opioid treatments.”
According to TipRanks’ statistics, out of the 3 analysts who have rated GWPH in the last 3 months, all 3 gave a Buy rating. The average 12-month price target for the stock is $141, marking a 69% upside from where shares last closed.
Costco Wholesale Corporation
Costco is set to release its Q1/2016 earnings on Tuesday, December 8 after market close. Analysts estimate that the company will post revenues of $27.65 billion and earnings of $1.17 per share, compared to last quarter’s revenues of $35.78 billion and earnings of $1.73 per share.
The company recently received negative media coverage with headlines that its Rotisserie Chicken Salad has been linked to E coli. Following this news, an investigation into the ingredients pointed to the vegetable mix as the culprit. In light of the scandal, analyst Oliver Chen of Cowen and Co assured investors they had nothing to worry about, reiterating his Outperform rating and $165 price target. He stated, “We’re cognizant that food scares are fluid situations and present negative headline risk, but we see minimal traffic risk to Costco thus far given small scale (19 people, 7 states), product already removed from stores, & it is a different E.coli strain/different states than CMG case.” Last week, the company reported its November sales figures, which were up 3% y/y.
According to TipRanks’ statistics, out of the 13 analysts who have rated Costco in the past 3 months, 10 gave a Buy rating while 3 remain on the sidelines. The average 12-month price target for the stock is $170.50, marking a 2% upside from where shares last closed.
OncoSec Medical Inc
ONCS will release its Q1/2016 earnings on Tuesday, December 8 after market close. Analyst expects the DNA-based intratumorial cancer immunotherapy company to post a loss per share of ($0.48), the same loss per share the company posted last quarter.
This quarter, the company issued a letter to shareholders indicating its plans for the next year. Furthermore, the company announced plans to advance its clinical pipeline, investigate new therapies and drug combinations, as well as finalize plans to move into a new facility. Last month, the company announced a $7.5 million agreement with institutional investors to purchase securities in exchange for shares of its common stock. The company intends to use these funds for R&D and clinical trials. CEO Punit Dhillion stated, “We are pleased with the support from healthcare focused funds as we continue to advance our immuno-oncology pipeline to fight cancer. This strategic financing allows the necessary cash runway to achieve our upcoming milestones while strengthening our balance sheet.”
According to TipRanks’ statistics, 1 analyst has rated ONCS in the last 3 months with a Buy rating. The average 12-month price target for the stock is $17, marking a 465% upside from where shares last closed.
Autozone is set to release its Q1/2016 earnings on Tuesday, December 8 before market open. For this quarter, analysts estimate the company will post revenues of $2.39 billion and earnings of $8.24 per share, compared to last quarter’s revenue of $3.3 billion and earnings of $12.75 per share.
Following last quarter’s earnings, the company announced Senior Vice President of Commercial and Customer Satisfaction Larry Roesel’s intent to retire. Roesel helped the company’s Commercial business grow from $700 million to $1.8 billion. Roesel stated, “It’s been a fantastic experience over the past 8 1/2 years. AutoZone is truly a unique and incredible organization driven by our strong ‘Customers First’ culture, exceptional leadership and the dedication and passion our 80,000 AutoZoners demonstrate every day. I’m extremely proud of the results we’ve delivered and the progress we’ve made with our Commercial business. I wish the team continued success for many years to come.”
According to TipRanks’ statistics, out of 5 analysts who rated AZO in the last 3 months, 2 gave a Buy rating while 5 remain on the sidelines. The average 12-month price target for the stock is $771, marking a 1% upside from where shares last closed.